BioMarin Pharmaceutical Inc. (BMRN) develops treatments for serious life-threatening medical conditions, mainly affecting children. The company’s top line is currently being driven by strong demand for its marketed products, especially new dwarfism drug, Voxzogo. Also, the recent approval of Roctavian (valoctocogene roxaparvovec, or valrox), a gene therapy for treating adults with severe hemophilia A, has opened up a key sales opportunity.BioMarin has an attractive early-stage pipeline primarily focusing on ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores a ...

The great advances and improvements in the treatment of diseases and the effectiveness of these medicines are undoubtedly due to technological progress and how biotech companies take advantage of it for their growth and development. Without the work of these companies, we would still be using very old and ineffective medicines. This new year brings with it very good opportunities to invest in companies in this sector. Here are these top biotech stocks to consider adding to your portfolio. Let’s take a look ...

Biomarin Pharmaceutical, Inc. (NASDAQ:BMRN) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Jean-Jacques Bienaime - Chairman and Chief Executive Officer Jeffrey Ajer - Chief Commercial Officer Henry Fuchs - President, Worldwide Research and Development Brian Mueller - Chief Financial Officer Greg Guyer - Chief Technical Officer, Manufacturing and Technical Operations Conference Call Participants Salveen Richter - Goldman Sachs Geof ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-26727 ______________________________________ BioMarin Pharmaceutical Inc ...

Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market ______________________________________ Form 10-Q Commission File Number: 000-26727 ______________________________________ BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) ______________________________________ Delaware 68-0397820 (State or other jurisdiction of incorpo ...

Biomarin Pharmaceutical, Inc. (NASDAQ:BMRN) Q2 2023 Earnings Conference Call July 31, 2023 4:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Jean-Jacques Bienaime - Chairman and Chief Executive Officer Jeffrey Ajer - Chief Commercial Officer Henry Fuchs - President, Worldwide Research and Development Brian Mueller - Chief Financial Officer Greg Guyer - Chief Technical Officer, Manufacturing and Technical Operations Conference Call Participants Akash Tewari - Jefferies Salveen Richte ...

| --- | --- | --- | --- | --- | --- | --- | |----------------------------------|-------------|---------------------------------------------------------------------------------------|-------|---------------------------------------------|-------|--------| | Assets: | Significant | Fair Value Measurements as of December 31, 2022 \n Other Observable Inputs (Level 2) | | Significant Unobservable Inputs (Level 3) | | Total | | Other current assets: | | | | | | | | NQDC Plan assets | $ | 2,654 | $ | — | $ | 2,654 ...

Biomarin Pharmaceutical, Inc. (NASDAQ:BMRN) Q1 2023 Earnings Conference Call April 26, 2023 4:30 PM ET Company Participants Traci McCarty - Group VP, IR Jean-Jacques Bienaime - Chairman & CEO Jeffrey Ajer - Chief Commercial Officer Henry Fuchs - President, Worldwide Research & Development Brian Mueller - CFO & EVP Conference Call Participants Salveen Richter - Goldman Sachs Group Geoffrey Meacham - Bank of America Merrill Lynch Christopher Raymond - Piper Sandler & Co. Timothy Lugo - William Blair & Company ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2022 Results Conference Call February 28, 2023 4:30 PM ET Company Participants Traci McCarty - Group VP, IR JJ Bienaimé - Chairman and CEO Jeff Ajer - EVP and Chief Commercial Officer Hank Fuchs - President, Worldwide R&D Greg Guyer - EVP and Chief Technical Officer Brian Mueller - EVP and CFO Conference Call Participants Salveen Richter - Goldman Sachs Geoff Meacham - Bank of America Phil Nadeau - Cowen and Company Jessica Fye - JPMorgan Chase Chris Raymond - P ...